XPEV vs. CRSP
XPEV (XPeng Inc.) and CRSP (CRISPR Therapeutics AG) are both stocks. XPEV operates in Auto Manufacturers (Consumer Cyclical), while CRSP operates in Biotechnology (Healthcare). Over the past 5 years, XPEV returned -18.98%/yr vs -17.08%/yr for CRSP. At a 0.35 correlation, their price movements are largely independent.
Performance
XPEV vs. CRSP - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, XPEV achieves a -28.55% return, which is significantly lower than CRSP's -5.03% return.
XPEV
- 1D
- 0.21%
- 1M
- -7.23%
- YTD
- -28.55%
- 6M
- -23.70%
- 1Y
- -20.30%
- 3Y*
- 12.09%
- 5Y*
- -18.98%
- 10Y*
- —
CRSP
- 1D
- -0.86%
- 1M
- 2.87%
- YTD
- -5.03%
- 6M
- -12.14%
- 1Y
- 20.41%
- 3Y*
- -6.43%
- 5Y*
- -17.08%
- 10Y*
- —
XPEV vs. CRSP - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|---|
XPEV XPeng Inc. | -28.55% | 71.57% | -18.99% | 46.78% | -80.25% | 17.51% | 85.41% |
CRSP CRISPR Therapeutics AG | -5.03% | 33.23% | -37.12% | 54.00% | -46.36% | -50.51% | 72.21% |
Correlation
The correlation between XPEV and CRSP is 0.21, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.21 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.27 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.35 |
Correlation (All Time) Calculated using the full available price history since Aug 27, 2020 | 0.35 |
The correlation between XPEV and CRSP shifts across timeframes, from 0.21 (1 year) to 0.35 (5 years), reflecting how their relationship changes across market environments.
Fundamentals
XPEV:
$6.92B
CRSP:
$4.78B
XPEV:
-CN¥3.15
CRSP:
-$6.24
XPEV:
0.95
CRSP:
1.11K
XPEV:
1.65
CRSP:
2.64
XPEV:
CN¥73.56B
CRSP:
$4.10M
XPEV:
CN¥14.61B
CRSP:
-$171.17M
XPEV:
-CN¥3.76B
CRSP:
-$509.21M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
XPEV vs. CRSP — Risk / Return Rank
XPEV
CRSP
XPEV vs. CRSP - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for XPeng Inc. (XPEV) and CRISPR Therapeutics AG (CRSP). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| XPEV | CRSP | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.78 | ||
| Sortino ratioReturn per unit of downside risk | -1.29 | ||
| Omega ratioGain probability vs. loss probability | 0.96 | 1.11 | -0.15 |
| Calmar ratioReturn relative to maximum drawdown | -0.51 | 0.49 | -1.00 |
| Martin ratioReturn relative to average drawdown | -0.89 | 0.81 | -1.70 |
Loading charts...
Drawdowns
XPEV vs. CRSP - Drawdown Comparison
The maximum XPEV drawdown since its inception was -91.12%, which is greater than CRSP's maximum drawdown of -85.11%. Use the drawdown chart below to compare losses from any high point for XPEV and CRSP.
Loading charts...
Drawdown Indicators
| XPEV | CRSP | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -91.12% | -85.11% | -6.01% |
Max Drawdown (1Y)Largest decline over 1 year | -48.49% | -42.25% | -6.24% |
Max Drawdown (3Y)Largest decline over 3 years | -71.65% | -64.91% | -6.74% |
Max Drawdown (5Y)Largest decline over 5 years | -88.35% | -80.68% | -7.67% |
Current DrawdownCurrent decline from peak | -79.92% | -76.29% | -3.63% |
Average DrawdownAverage peak-to-trough decline | -67.89% | -49.24% | -18.65% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 27.68% | 25.51% | +2.17% |
Volatility
XPEV vs. CRSP - Volatility Comparison
The current volatility for XPeng Inc. (XPEV) is 14.02%, while CRISPR Therapeutics AG (CRSP) has a volatility of 18.22%. This indicates that XPEV experiences smaller price fluctuations and is considered to be less risky than CRSP based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| XPEV | CRSP | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 14.02% | 18.22% | -4.20% |
Volatility (6M)Calculated over the trailing 6-month period | 35.62% | 43.62% | -8.00% |
Volatility (1Y)Calculated over the trailing 1-year period | 55.48% | 62.44% | -6.96% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 78.68% | 60.65% | +18.03% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 83.39% | 64.35% | +19.04% |
Dividends
XPEV vs. CRSP - Dividend Comparison
Neither XPEV nor CRSP has paid dividends to shareholders.
Financials
XPEV vs. CRSP - Financials Comparison
This section allows you to compare key financial metrics between XPeng Inc. and CRISPR Therapeutics AG. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
XPEV and CRSP have a correlation of 0.21, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
CRSP has higher volatility (18.22%) compared to XPEV (14.02%). In terms of maximum drawdown, XPEV dropped -91.12% vs CRSP's -85.11%.
CRSP currently has the higher Sharpe Ratio (0.33 vs -0.45), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for XPEV and CRSP
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer